TY - JOUR
T1 - Are national policies and programs for prevention and management of postpartum hemorrhage and preeclampsia adequate? A key informant survey in 37 countries
AU - Smith, Jeffrey Michael
AU - Currie, Sheena
AU - Cannon, Tirza
AU - Armbruster, Deborah
AU - Perri, Julia
N1 - Funding Information:
Acknowledgments: The authors would like to acknowledge the United States Agency for International Development (USAID), through its support to the Maternal and Child Health Integrated Program (MCHIP), implemented by Jhpiego and its partners, for its assistance with this paper as well as national Ministries of Health, related government partners, committees, and maternal and reproductive health working groups for their contributions.
Funding Information:
With this in mind, the Maternal and Child Health Integrated Program (MCHIP), with support from the United States Agency for International Development (USAID), undertook an augmented key informant survey in 2012 of national health programs supported by USAID in 43 countries, especially those facing the highest burden of maternal mortality. The goal of this multi-country survey was to provide a global snapshot of the extent to which these essential policies and programs were in place and to provide program managers and development partners with evidence on the key processes that facilitate scale up and expansion of maternal health interventions, especially evidence-based PPH and PE/E program interventions. This article summarizes the most relevant findings from the 2012 survey. The full report, including the questionnaires (in English, French, and Spanish), is available at: www.mchip.net/global statusreportdownloads.
PY - 2014/8
Y1 - 2014/8
N2 - Introduction: Although maternal mortality has declined substantially in recent years, efforts to address postpartum hemorrhage (PPH) and preeclampsia/eclampsia (PE/E) must be systematically scaled up in order for further reduction to take place. In 2012, a key informant survey was conducted to identify both national and global gaps in PPH and PE/E program priorities and to highlight focus areas for future national and global programming. Methods: Between January and March 2012, national program teams in 37 countries completed a 44-item survey, consisting mostly of dichotomous yes/no responses and addressing 6 core programmatic areas: policy, training, medication distribution and logistics, national reporting of key indicators, programming, and challenges to and opportunities for scale up. An in-country focal person led the process to gather the necessary information from key local stakeholders. Some countries also provided national essential medicines lists and service delivery guidelines for comparison and further analysis. Results: Most surveyed countries have many elements in place to address PPH and PE/E, but notable gaps remain in both policy and practice. Oxytocin and magnesium sulfate were reported to be regularly available in facilities in 89% and 76% of countries, respectively. Only 27% of countries, however, noted regular availability of misoprostol in health facilities. Midwife scope of practice regarding PPH and PE/E is inconsistent with global norms in a number of countries: 22% of countries do not allow midwives to administer magnesium sulfate and 30% do not allow them to perform manual removal of the placenta. Conclusions: Most countries surveyed have many of the essential policies and program elements to prevent/manage PPH and PE/E, but absence of commodities (especially misoprostol), limitations in scope of practice for midwives, and gaps in inclusion of maternal health indicators in the national data systems have impeded efforts to scale up programs nationally.
AB - Introduction: Although maternal mortality has declined substantially in recent years, efforts to address postpartum hemorrhage (PPH) and preeclampsia/eclampsia (PE/E) must be systematically scaled up in order for further reduction to take place. In 2012, a key informant survey was conducted to identify both national and global gaps in PPH and PE/E program priorities and to highlight focus areas for future national and global programming. Methods: Between January and March 2012, national program teams in 37 countries completed a 44-item survey, consisting mostly of dichotomous yes/no responses and addressing 6 core programmatic areas: policy, training, medication distribution and logistics, national reporting of key indicators, programming, and challenges to and opportunities for scale up. An in-country focal person led the process to gather the necessary information from key local stakeholders. Some countries also provided national essential medicines lists and service delivery guidelines for comparison and further analysis. Results: Most surveyed countries have many elements in place to address PPH and PE/E, but notable gaps remain in both policy and practice. Oxytocin and magnesium sulfate were reported to be regularly available in facilities in 89% and 76% of countries, respectively. Only 27% of countries, however, noted regular availability of misoprostol in health facilities. Midwife scope of practice regarding PPH and PE/E is inconsistent with global norms in a number of countries: 22% of countries do not allow midwives to administer magnesium sulfate and 30% do not allow them to perform manual removal of the placenta. Conclusions: Most countries surveyed have many of the essential policies and program elements to prevent/manage PPH and PE/E, but absence of commodities (especially misoprostol), limitations in scope of practice for midwives, and gaps in inclusion of maternal health indicators in the national data systems have impeded efforts to scale up programs nationally.
UR - http://www.scopus.com/inward/record.url?scp=84929503324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929503324&partnerID=8YFLogxK
U2 - 10.9745/GHSP-D-14-00034
DO - 10.9745/GHSP-D-14-00034
M3 - Article
C2 - 25276587
AN - SCOPUS:84929503324
SN - 2169-575X
VL - 2
SP - 275
EP - 284
JO - Global Health Science and Practice
JF - Global Health Science and Practice
IS - 3
ER -